Industries > Pharma > Pharmaceutical Excipients Market Report 2021-2031
Pharmaceutical Excipients Market Report 2021-2031
By Product (Organic Chemicals, Inorganic Chemicals, and Other Chemicals), By Functionality (Fillers & Diluents, Suspending & Viscosity Agents, Coating Agents, Binders, Flavoring Agents & Sweeteners, Disintegrants, Colorants, Lubricants & Glidants, Preservatives, Emulsifying Agents, and Other Functionalities), By Type of Formulation (Oral Formulations, Topical Formulations, Parenteral Formulations, and Other Formulations), By Patient Demographics (Adults, Geriatric, Pediatric), By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Leading Regional/ Country market analysis
Pharmaceutical Excipients Market– our new study reveals trends, R&D progress, and predicted revenues
Where the Pharmaceutical Excipients is market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our 280+ page report provides 410+ tables and 390+ charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Pharmaceutical Excipients Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
• Revenue and growth forecasts from 2021 to 2031 for the Global Pharmaceutical Excipients Market By Product
• Organic Chemicals
o Oleochemicals
Fatty Alcohols
Mineral Stearates
Glycerin
Other Oleochemicals
o Carbohydrates
Sugars
• Actual Sugars
o Lactose
o Sucrose
o Dextrose (D-Glucose)
• Sugar Alcohols
o Mannitol
o Sorbitol
o Other Sugar Alcohols
• Artificial Sweeteners
Cellulose
• Microcrystalline Cellulose
• Cellulose Ethers
• CMC and Croscarmellose Sodium
• Cellulose Esters
Starch
• Modified Starch
• Dried Starch
• Converted Starch
o Petrochemicals
Glycols
• Polyethylene Glycol
• Propylene Glycol
Povidones
Mineral Hydrocarbons
• PetRoLAtum
• Mineral Waxes
• Mineral Oils
Acrylic Polymers
Other Petrochemicals
o Proteins
• Inorganic Chemicals
o Calcium Phosphate
o Metal Oxides
o Halites
o Calcium Carbonate
o Calcium Sulfate
o Other Inorganic Chemicals
• Other Chemicals
• Revenue and growth forecasts from 2021 to 2031 for the Global Pharmaceutical Excipients Market By Functionality
• Fillers & Diluents
• Suspending & Viscosity Agents
• Coating Agents
• Binders
• Flavoring Agents & Sweeteners
• Disintegrants
• Colorants
• Lubricants & Glidants
• Preservatives
• Emulsifying Agents
• Other Functionalities
• Revenue and growth forecasts from 2021 to 2031 for the Global Pharmaceutical Excipients Market By Type of Formulation
• Oral Formulations
o Tablets
o Capsules
Hard Gelatin Capsules
Soft Gelatin Capsules
o Liquid Formulations
• Topical Formulations
• Parenteral Formulations
• Other Formulations
• Revenue and growth forecasts from 2021 to 2031 for the Global Pharmaceutical Excipients Market By Patient Demographics
• Adults
• Geriatric
• Pediatric
• Revenue and growth forecasts from 2021 to 2031 for the Global Pharmaceutical Excipients Market By End User
• Hospitals
• Homecare
• Specialty Clinics
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Pharmaceutical Excipients Market By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• Middle East and Africa
o Turkey
o Saudi Arabia
o South Africa
o UAE
o Egypt
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Pharmaceutical Excipients Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Pharmaceutical Excipients Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Pharmaceutical Excipients Market report helps you
In summary, our 280+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Pharmaceutical Excipients Market, with forecasts for Get our report today Pharmaceutical Excipients Market Forecast 2021-2031: By Product, Functionality, Type of Formulation, Patient Demographics, End User, Distribution Channel and Leading Regional/ Country market analysis each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Pharmaceutical Excipients market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Pharmaceutical Excipients Market. Some of the company’s profiled in this report include
• Dupont De Nemours, Inc.
• Roquette Frères
• Ashland Global Holdings Inc.
• Evonik Industries AG
• BASF SE
• Kerry Group PLC
• Croda International
• Associated British Foods PLC
• Archer Daniels Midland Company
• Lubrizol Corporation
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Pharmaceutical Excipients Market and leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Pharmaceutical Excipients Market Report 2021-2031: By Product (Organic Chemicals, Inorganic Chemicals, and Other Chemicals), By Functionality (Fillers & Diluents, Suspending & Viscosity Agents, Coating Agents, Binders, Flavoring Agents & Sweeteners, Disintegrants, Colorants, Lubricants & Glidants, Preservatives, Emulsifying Agents, and Other Functionalities), By Type of Formulation (Oral Formulations, Topical Formulations, Parenteral Formulations, and Other Formulations), By Patient Demographics (Adults, Geriatric, Pediatric), By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Leading Regional/ Country market analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Pharmaceutical Excipients Market
2.1. Pharmaceutical Excipients Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Condition Submarkets Definitions
3. Pharmaceutical Excipients Market Overview
3.1. Global Pharmaceutical Excipients Market Size and Forecast By Region
3.2. Global Pharmaceutical Excipients Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Rapid Surge in the generics demand
3.3.1.2. Increasing geriatric population around the world
3.3.1.3. Increasing strategic initiatives in pharmaceutical excipients market
3.3.1.4. Growing regulatory approvals
3.3.2. Market Restraints
3.3.2.1. Stringent regulation associated with product development
3.3.2.2. High cost of development
3.3.3. Opportunities
3.3.3.1. Increasing therapeutic advancements in pharmaceutical excipients
3.3.3.2. Increasing investment in the pharmaceutical excipients
3.3.4. Challenges
3.3.4.1. Increasing environment concerns around the world
3.3.4.2. Rapid changes in export & import policies
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Pharmaceutical Excipients Market Analysis and Forecast 2021-2031, By Product (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Organic Chemicals
4.1.1.1. Organic Chemicals market size and forecast, 2021-2031 (USD Million)
4.1.2. Inorganic Chemicals
4.1.2.1. Inorganic Chemicals market size and forecast, 2021-2031 (USD Million)
4.1.3. Other Chemicals
4.1.3.1. Other Chemicals market size and forecast, 2021-2031 (USD Million)
5. Global Pharmaceutical Excipients Market Analysis and Forecast, 2021-2031 By Functionality (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Fillers & Diluents
5.1.1.1. Fillers & Diluents market size and forecast, 2021-2031 (USD Million)
5.1.2. Suspending & Viscosity Agents
5.1.2.1. Suspending & Viscosity Agents market size and forecast, 2021-2031 (USD Million)
5.1.3. Coating Agents
5.1.3.1. Coating Agents market size and forecast, 2021-2031 (USD Million)
5.1.4. Binders
5.1.4.1. Binders market size and forecast, 2021-2031 (USD Million)
5.1.5. Flavoring Agents & Sweeteners
5.1.5.1. Flavoring Agents & Sweeteners market size and forecast, 2021-2031 (USD Million)
5.1.6. Disintegrants
5.1.6.1. Disintegrants market size and forecast, 2021-2031 (USD Million)
5.1.7. Colorants
5.1.7.1. Colorants market size and forecast, 2021-2031 (USD Million)
5.1.8. Lubricants & Glidants
5.1.8.1. Lubricants & Glidants market size and forecast, 2021-2031 (USD Million)
5.1.9. Preservatives
5.1.9.1. Preservatives market size and forecast, 2021-2031 (USD Million)
5.1.10. Emulsifying Agents
5.1.10.1. Emulsifying Agents market size and forecast, 2021-2031 (USD Million)
5.1.11. Others
5.1.11.1. Others market size and forecast, 2021-2031 (USD Million)
6. Global Pharmaceutical Excipients Market Analysis and Forecast, 2021-2031 By Patient Demographics (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Geriatric
6.1.1.1. Geriatric market size and forecast, 2021-2031 (USD Million)
6.1.2. Adult
6.1.2.1. Adult market size and forecast, 2021-2031 (USD Million)
6.1.3. Pediatric
6.1.3.1. Pediatric market size and forecast, 2021-2031 (USD Million)
7. Global Pharmaceutical Excipients Market Analysis and Forecast, 2021-2031 Type of Formulation (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Oral Formulations
7.1.1.1. Oral Formulations market size and forecast, 2021-2031 (USD Million)
7.1.2. Topical Formulations
7.1.2.1. Topical Formulations market size and forecast, 2021-2031 (USD Million)
7.1.3. Parenteral Formulations
7.1.3.1. Parenteral Formulations market size and forecast, 2021-2031 (USD Million)
7.1.4. Other Formulations
7.1.4.1. Other Formulations market size and forecast, 2021-2031 (USD Million)
8. Global Pharmaceutical Excipients Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Hospitals
8.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
8.1.2. Homecare
8.1.2.1. Homecare market size and forecast, 2021-2031 (USD Million)
8.1.3. Specialty Clinics
8.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
8.1.4. Others
8.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
9. Global Pharmaceutical Excipients Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.1.1. Hospitals Pharmacy
9.1.1.1. Hospitals Pharmacy market size and forecast, 2021-2031 (USD Million)
9.1.2. Retail Pharmacy
9.1.2.1. Retail Pharmacy market size and forecast, 2021-2031 (USD Million)
9.1.3. Online Pharmacies
9.1.3.1. Online Pharmacies market size and forecast, 2021-2031 (USD Million)
10. North America Pharmaceutical Excipients Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. North America Pharmaceutical Excipients Market Size and Forecast By Product
10.2.1.1. XX Driving/Opportunity Factor
10.2.1.2. XX Driving/Opportunity Factor
10.3. North America Pharmaceutical Excipients Market Size and Forecast By Functionality
10.3.1.1. XX Driving/Opportunity Factor
10.3.1.2. XX Driving/Opportunity Factor
10.4. North America Pharmaceutical Excipients Market Size and Forecast Type of Formulation
10.4.1.1. XX Driving/Opportunity Factor
10.4.1.2. XX Driving/Opportunity Factor
10.5. North America Pharmaceutical Excipients Market Size and Forecast By Patient Demographics
10.5.1.1. XX Driving/Opportunity Factor
10.5.1.2. XX Driving/Opportunity Factor
10.6. North America Pharmaceutical Excipients Market Size and Forecast By End-User
10.6.1.1. XX Driving/Opportunity Factor
10.6.1.2. XX Driving/Opportunity Factor
10.7. North America Pharmaceutical Excipients Market Size and Forecast By Distribution Channel
10.7.1.1. XX Driving/Opportunity Factor
10.7.1.2. XX Driving/Opportunity Factor
10.8. U.S. Pharmaceutical Excipients Market
10.8.1.1. XX Driving/Opportunity Factor
10.8.1.2. XX Driving/Opportunity Factor
10.9. Canada Pharmaceutical Excipients Market
10.9.1.1. XX Driving/Opportunity Factor
10.9.1.2. XX Driving/Opportunity Factor
11. Europe Pharmaceutical Excipients Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. Europe Pharmaceutical Excipients Market Size and Forecast By Product
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. Europe Pharmaceutical Excipients Market Size and Forecast By Functionality
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. Europe Pharmaceutical Excipients Market Size and Forecast By Patient Demographics
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. Europe Pharmaceutical Excipients Market Size and Forecast Type of Formulation
11.5.1.1. XX Driving/Opportunity Factor
11.5.1.2. XX Driving/Opportunity Factor
11.6. Europe Pharmaceutical Excipients Market Size and Forecast By End-User
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. Europe Pharmaceutical Excipients Market Size and Forecast By Distribution Channel
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. UK Pharmaceutical Excipients Market
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
11.9. Germany Pharmaceutical Excipients Market
11.9.1.1. XX Driving/Opportunity Factor
11.9.1.2. XX Driving/Opportunity Factor
11.10. France Pharmaceutical Excipients Market
11.10.1.1. XX Driving/Opportunity Factor
11.10.1.2. XX Driving/Opportunity Factor
11.11. Rest of Europe Pharmaceutical Excipients Market
11.11.1.1. XX Driving/Opportunity Factor
11.11.1.2. XX Driving/Opportunity Factor
12. Asia Pacific Pharmaceutical Excipients Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. Asia-Pacific Pharmaceutical Excipients Market Size and Forecast By Product
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. Asia-Pacific Pharmaceutical Excipients Market Size and Forecast By Functionality
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. Asia-Pacific Pharmaceutical Excipients Market Size and Forecast By Patient Demographics
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. Asia-Pacific Pharmaceutical Excipients Market Size and Forecast Type of Formulation
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. Asia-Pacific Pharmaceutical Excipients Market Size and Forecast By End-User
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. Asia-Pacific Pharmaceutical Excipients Market Size and Forecast By Distribution Channel
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. China Pharmaceutical Excipients Market
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. India Pharmaceutical Excipients Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
12.10. Japan Pharmaceutical Excipients Market
12.10.1.1. XX Driving/Opportunity Factor
12.10.1.2. XX Driving/Opportunity Factor
12.11. Rest of Asia Pacific Pharmaceutical Excipients Market
12.11.1.1. XX Driving/Opportunity Factor
12.11.1.2. XX Driving/Opportunity Factor
13. Latin America Pharmaceutical Excipients Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. Latin America Pharmaceutical Excipients Market Size and Forecast By Product
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. Latin America Pharmaceutical Excipients Market Size and Forecast By Functionality
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. Latin America Pharmaceutical Excipients Market Size and Forecast By Patient Demographics
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. Latin America Pharmaceutical Excipients Market Size and Forecast Type of Formulation
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. Latin America Pharmaceutical Excipients Market Size and Forecast By End-User
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. Latin America Pharmaceutical Excipients Market Size and Forecast By Distribution Channel
13.8. Brazil Pharmaceutical Excipients Market
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. Mexico Pharmaceutical Excipients Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
13.10. Rest of Latin America Pharmaceutical Excipients Market
13.10.1.1. XX Driving/Opportunity Factor
13.10.1.2. XX Driving/Opportunity Factor
14. MEA Pharmaceutical Excipients Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
14.1. Market Overview
14.2. MEA Pharmaceutical Excipients Market Size and Forecast By Product
14.2.1.1. XX Driving/Opportunity Factor
14.2.1.2. XX Driving/Opportunity Factor
14.3. MEA Pharmaceutical Excipients Market Size and Forecast By Functionality
14.3.1.1. XX Driving/Opportunity Factor
14.3.1.2. XX Driving/Opportunity Factor
14.4. MEA Pharmaceutical Excipients Market Size and Forecast By Patient Demographics
14.4.1.1. XX Driving/Opportunity Factor
14.4.1.2. XX Driving/Opportunity Factor
14.5. MEA Pharmaceutical Excipients Market Size and Forecast Type of Formulation
14.5.1.1. XX Driving/Opportunity Factor
14.5.1.2. XX Driving/Opportunity Factor
14.6. MEA Pharmaceutical Excipients Market Size and Forecast By End-User
14.6.1.1. XX Driving/Opportunity Factor
14.6.1.2. XX Driving/Opportunity Factor
14.7. MEA Pharmaceutical Excipients Market Size and Forecast By Distribution Channel
14.7.1.1. XX Driving/Opportunity Factor
14.7.1.2. XX Driving/Opportunity Factor
14.8. GCC Pharmaceutical Excipients Market
14.8.1.1. XX Driving/Opportunity Factor
14.8.1.2. XX Driving/Opportunity Factor
14.9. South Africa Pharmaceutical Excipients Market
14.9.1.1. XX Driving/Opportunity Factor
14.9.1.2. XX Driving/Opportunity Factor
14.10. Rest of MEA Pharmaceutical Excipients Market
14.10.1.1. XX Driving/Opportunity Factor
14.10.1.2. XX Driving/Opportunity Factor
15. Companies in the Pharmaceutical Excipients Market
15.1. Dupont De Nemours, Inc.
15.1.1. Company Snapshot
15.1.2. Company Overview
15.1.3. Financial Performance (2015-2019)
15.1.3.1. Net Revenue
15.1.3.2. Gross Profit
15.1.3.3. Geographical Revenue, 2019
15.1.4. Product Offerings
15.1.5. Recent Initiatives (2017-2019)
15.2. Roquette Frères
15.2.1. Company Snapshot
15.2.2. Company Overview
15.2.3. Financial Performance (2015-2019)
15.2.3.1. Net Revenue
15.2.3.2. Gross Profit
15.2.3.3. Geographical Revenue, 2019
15.2.4. Product Offerings
15.2.5. Recent Initiatives (2017-2019)
15.3. Ashland Global Holdings Inc.
15.3.1. Company Snapshot
15.3.2. Company Overview
15.3.3. Financial Performance (2015-2019)
15.3.3.1. Net Revenue
15.3.3.2. Gross Profit
15.3.3.3. Geographical Revenue, 2019
15.3.4. Product Offerings
15.3.5. Recent Initiatives (2017-2019)
15.4. Evonik Industries AG
15.4.1. Company Snapshot
15.4.2. Company Overview
15.4.3. Financial Performance (2015-2019)
15.4.3.1. Net Revenue
15.4.3.2. Gross Profit
15.4.3.3. Geographical Revenue, 2019
15.4.4. Product Offerings
15.4.5. Recent Initiatives (2017-2019)
15.5. BASF SE
15.5.1. Company Snapshot
15.5.2. Company Overview
15.5.3. Financial Performance (2015-2019)
15.5.3.1. Net Revenue
15.5.3.2. Gross Profit
15.5.3.3. Geographical Revenue, 2019
15.5.4. Product Offerings
15.5.5. Recent Initiatives (2017-2019)
15.6. Kerry Group PLC
15.6.1. Company Snapshot
15.6.2. Company Overview
15.6.3. Financial Performance (2015-2019)
15.6.3.1. Net Revenue
15.6.3.2. Gross Profit
15.6.3.3. Geographical Revenue, 2019
15.6.4. Product Offerings
15.6.5. Recent Initiatives (2017-2019)
15.7. Croda International
15.7.1. Company Snapshot
15.7.2. Company Overview
15.7.3. Financial Performance (2015-2019)
15.7.3.1. Net Revenue
15.7.3.2. Gross Profit
15.7.3.3. Geographical Revenue, 2019
15.7.4. Product Offerings
15.7.5. Recent Initiatives (2017-2019)
15.8. Associated British Foods PLC
15.8.1. Company Snapshot
15.8.2. Company Overview
15.8.3. Financial Performance (2015-2019)
15.8.3.1. Net Revenue
15.8.3.2. Gross Profit
15.8.3.3. Geographical Revenue, 2019
15.8.4. Product Offerings
15.8.5. Recent Initiatives (2017-2019)
15.9. Archer Daniels Midland Company
15.9.1. Company Snapshot
15.9.2. Company Overview
15.9.3. Financial Performance (2015-2019)
15.9.3.1. Net Revenue
15.9.3.2. Gross Profit
15.9.3.3. Geographical Revenue, 2019
15.9.4. Product Offerings
15.9.5. Recent Initiatives (2017-2019)
15.10. Lubrizol Corporation
15.10.1. Company Snapshot
15.10.2. Company Overview
15.10.3. Financial Performance (2015-2019)
15.10.3.1. Net Revenue
15.10.3.2. Gross Profit
15.10.3.3. Geographical Revenue, 2019
15.10.4. Product Offerings
15.10.5. Recent Initiatives (2017-2019)
15.11. Other Notable Players
16. Conclusion
17. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Pharmaceutical Excipients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Pharmaceutical Excipients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Pharmaceutical Excipients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Pharmaceutical Excipients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Pharmaceutical Excipients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Pharmaceutical Excipients Market Drivers & Restraints 2021
Table 7. Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Organic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Organic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Organic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Organic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Organic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Inorganic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Inorganic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Inorganic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Inorganic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Inorganic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Other Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Other Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Other Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Other Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Other Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Fillers & Diluents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Fillers & Diluents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Fillers & Diluents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Fillers & Diluents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Fillers & Diluents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Suspending & Viscosity Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Suspending & Viscosity Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Suspending & Viscosity Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Suspending & Viscosity Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Suspending & Viscosity Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Coating Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Coating Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Coating Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Coating Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Coating Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Binders Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Binders Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Binders Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Binders Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Binders Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Disintegrants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Disintegrants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Disintegrants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Disintegrants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Disintegrants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Colorants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Colorants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Colorants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Colorants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Colorants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Lubricants & Glidants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Lubricants & Glidants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Lubricants & Glidants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Lubricants & Glidants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Lubricants & Glidants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Preservatives Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Preservatives Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Preservatives Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Preservatives Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Preservatives Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Emulsifying Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Emulsifying Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Emulsifying Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Emulsifying Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Emulsifying Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Parenteral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Parenteral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Parenteral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Parenteral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Parenteral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Oral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Oral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Oral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Oral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Oral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Topical Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Topical Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Topical Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Topical Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Topical Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Other Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 123. Other Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Other Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Other Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Other Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 128. Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 133. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 138. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 143. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 146. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 148. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 153. Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 158. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 163. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 168. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 172. North America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. North America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. North America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. North America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. North America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. North America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. North America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. North America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. North America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. North America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. North America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. North America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. North America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. North America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. North America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. North America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. North America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. North America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. North America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. North America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. North America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. North America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. North America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. North America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. North America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. North America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. North America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. North America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. North America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. North America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. North America Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. North America Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. North America Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. North America Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. North America Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. US Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. US Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. US Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. US Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. US Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212. Canada Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213. Canada Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. Canada Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. Canada Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. Canada Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. Europe Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 218. Europe Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219. Europe Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. Europe Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. Europe Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222. Europe Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 223. Europe Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224. Europe Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225. Europe Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226. Europe Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227. Europe Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 228. Europe Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 229. Europe Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 230. Europe Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 231. Europe Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 232. Europe Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 233. Europe Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 234. Europe Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 235. Europe Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 236. Europe Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 237. Europe Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 238. Europe Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 239. Europe Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 240. Europe Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 241. Europe Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 242. Europe Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 243. Europe Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 244. Europe Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 245. Europe Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 246. Europe Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 247. Europe Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 248. Europe Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 249. Europe Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 250. Europe Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 251. UK Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 252. UK Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 253. UK Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 254. UK Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 255. UK Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 256. Germany Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 257. Germany Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 258. Germany Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 259. Germany Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 260. Germany Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 261. France Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 262. France Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 263. France Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 264. France Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 265. France Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 266. Rest of Europe Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 267. Rest of Europe Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 268. Rest of Europe Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 269. Rest of Europe Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 270. Rest of Europe Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 271. Asia Pacific Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 272. Asia Pacific Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 273. Asia Pacific Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 274. Asia Pacific Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 275. Asia Pacific Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 276. Asia Pacific Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 277. Asia Pacific Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 278. Asia Pacific Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 279. Asia Pacific Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 280. Asia Pacific Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 281. Asia Pacific Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 282. Asia Pacific Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 283. Asia Pacific Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 284. Asia Pacific Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 285. Asia Pacific Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 286. Asia Pacific Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 287. Asia Pacific Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 288. Asia Pacific Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 289. Asia Pacific Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 290. Asia Pacific Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 291. Asia Pacific Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 292. Asia Pacific Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 293. Asia Pacific Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 294. Asia Pacific Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 295. Asia Pacific Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 296. Asia Pacific Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 297. Asia Pacific Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 298. Asia Pacific Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 299. Asia Pacific Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 300. Asia Pacific Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 301. Asia Pacific Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 302. Asia Pacific Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 303. Asia Pacific Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 304. Asia Pacific Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 305. Asia Pacific Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 306. China Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 307. China Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 308. China Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 309. China Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 310. China Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 311. India Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 312. India Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 313. India Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 314. India Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 315. India Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 316. Japan Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 317. Japan Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 318. Japan Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 319. Japan Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 320. Japan Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 321. RoAPAC Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 322. RoAPAC Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 323. RoAPAC Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 324. RoAPAC Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 325. RoAPAC Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 326. Middle East Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 327. Middle East Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 328. Middle East Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 329. Middle East Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 330. Middle East Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 331. Middle East Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 332. Middle East Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 333. Middle East Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 334. Middle East Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 335. Middle East Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 336. Middle East Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 337. Middle East Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 338. Middle East Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 339. Middle East Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 340. Middle East Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 341. Middle East Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 342. Middle East Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 343. Middle East Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 344. Middle East Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 345. Middle East Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 346. Middle East Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 347. Middle East Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 348. Middle East Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 349. Middle East Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 350. Middle East Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 351. Middle East Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 352. Middle East Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 353. Middle East Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 354. Middle East Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 355. Middle East Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 356. Latin America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 357. Latin America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 358. Latin America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 359. Latin America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 360. Latin America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 361. Latin America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 362. Latin America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 363. Latin America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 364. Latin America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 365. Latin America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 366. Latin America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 367. Latin America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 368. Latin America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 369. Latin America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 370. Latin America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 371. Latin America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 372. Latin America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 373. Latin America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 374. Latin America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 375. Latin America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 376. Latin America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 377. Latin America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 378. Latin America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 379. Latin America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 380. Latin America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 381. Latin America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 382. Latin America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 383. Latin America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 384. Latin America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 385. Latin America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 386. Africa Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 387. Africa Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 388. Africa Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 389. Africa Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 390. Africa Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 391. Africa Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 392. Africa Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 393. Africa Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 394. Africa Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 395. Africa Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 396. Africa Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 397. Africa Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 398. Africa Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 399. Africa Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 400. Africa Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 401. Africa Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 402. Africa Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 403. Africa Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 404. Africa Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 405. Africa Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 406. Africa Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 407. Africa Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 408. Africa Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 409. Africa Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 410. Africa Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 411. Africa Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 412. Africa Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 413. Africa Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 414. Africa Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 415. Africa Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 416. Leading 10 Pharmaceutical Excipients Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 417. Dupont De Nemours, Inc.Profile 2019 (CEO, HQ, Founded, Website)
Table 418. Dupont De Nemours, Inc. Pharmaceutical Excipients Product Offering (Segment, Product Offerings)
Table 419. Roquette Frères Profile 2019 (CEO, HQ, Founded, Website)
Table 420. Roquette Frères Pharmaceutical Excipients Product Offering (Segment, Product Offerings)
Table 421. Ashland Global Holdings Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 422. Ashland Global Holdings Inc..Pharmaceutical Excipients Product Offering (Segment, Product Offerings)
Table 423. Evonik Industries AG Profile 2019 (CEO, HQ, Founded, Website)
Table 424. Evonik Industries AG Pharmaceutical Excipients Product Offering (Segment, Product Offerings)
Table 425. BASF SE Profile 2019 (CEO, HQ, Founded, Website)
Table 426. BASF SE Pharmaceutical Excipients Product Offering (Segment, Product Offerings)
Table 427. Kerry Group PLC Profile 2019 (CEO, HQ, Founded, Website)
Table 428. Kerry Group PLC Pharmaceutical Excipients Product Offering (Segment, Product Offerings)
Table 429. Croda International Profile 2019 (CEO, HQ, Founded, Website)
Table 430. Croda International Pharmaceutical Excipients Product Offering (Segment, Product Offerings)
Table 431. Associated British Foods PLC Profile 2019 (CEO, HQ, Founded, Website)
Table 432. Associated British Foods PLC Pharmaceutical Excipients Product Offering (Segment, Product Offerings)
Table 433. Archer Daniels Midland Company Profile 2019 (CEO, HQ, Founded, Website)
Table 434. Archer Daniels Midland Company Pharmaceutical Excipients Product Offering (Segment, Product Offerings)
Table 435. Lubrizol Corporation Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 436. Lubrizol Corporation Pharmaceutical Excipients Product Offering (Segment, Product Offerings)
Table 437. Other Companies Involved in the Pharmaceutical Excipients Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Pharmaceutical Excipients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Pharmaceutical Excipients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Pharmaceutical Excipients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Pharmaceutical Excipients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Pharmaceutical Excipients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Pharmaceutical Excipients Market Drivers & Restraints 2021
Figure 7. Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. Organic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. Organic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. Organic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. Organic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. Organic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Inorganic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Inorganic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Inorganic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Inorganic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Inorganic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Other Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Other Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Other Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Other Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Other Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Fillers & Diluents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33. Fillers & Diluents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Fillers & Diluents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Fillers & Diluents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Fillers & Diluents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Suspending & Viscosity Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Suspending & Viscosity Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Suspending & Viscosity Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Suspending & Viscosity Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Suspending & Viscosity Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Coating Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Coating Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Coating Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Coating Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Coating Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Binders Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Binders Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Binders Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Binders Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Binders Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Disintegrants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Disintegrants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Disintegrants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Disintegrants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Disintegrants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Colorants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Colorants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Colorants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Colorants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Colorants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Lubricants & Glidants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Lubricants & Glidants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Lubricants & Glidants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Lubricants & Glidants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Lubricants & Glidants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Preservatives Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Preservatives Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Preservatives Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Preservatives Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Preservatives Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Emulsifying Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Emulsifying Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Emulsifying Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Emulsifying Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Emulsifying Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Parenteral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Parenteral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Parenteral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Parenteral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Parenteral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Oral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Oral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Oral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Oral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Oral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. Topical Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 118. Topical Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. Topical Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. Topical Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. Topical Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. Other Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 123. Other Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. Other Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. Other Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. Other Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 128. Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 133. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 138. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 143. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 148. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 153. Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 158. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 163. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 168. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. North America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 173. North America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 174. North America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 175. North America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 176. North America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 177. North America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 178. North America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 179. North America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 180. North America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 181. North America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 182. North America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 183. North America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 184. North America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 185. North America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 186. North America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 187. North America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 188. North America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 189. North America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 190. North America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 191. North America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 192. North America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 193. North America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 194. North America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 195. North America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 196. North America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 197. North America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 198. North America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 199. North America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 200. North America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 201. North America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 202. North America Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 203. North America Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 204. North America Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 205. North America Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 206. North America Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 207. US Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 208. US Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 209. US Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 210. US Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 211. US Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 212. Canada Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 213. Canada Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 214. Canada Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 215. Canada Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 216. Canada Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 217. Europe Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 218. Europe Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 219. Europe Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 220. Europe Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 221. Europe Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 222. Europe Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 223. Europe Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 224. Europe Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 225. Europe Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 226. Europe Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 227. Europe Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 228. Europe Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 229. Europe Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 230. Europe Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 231. Europe Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 232. Europe Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 233. Europe Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 234. Europe Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 235. Europe Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 236. Europe Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 237. Europe Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 238. Europe Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 239. Europe Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 240. Europe Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 241. Europe Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 242. Europe Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 243. Europe Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 244. Europe Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 245. Europe Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 246. Europe Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 247. Europe Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 248. Europe Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 249. Europe Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 250. Europe Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 251. UK Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 252. UK Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 253. UK Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 254. UK Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 255. UK Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 256. Germany Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 257. Germany Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 258. Germany Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 259. Germany Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 260. Germany Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 261. France Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 262. France Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 263. France Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 264. France Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 265. France Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 266. Rest of Europe Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 267. Rest of Europe Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 268. Rest of Europe Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 269. Rest of Europe Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 270. Rest of Europe Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 271. Asia Pacific Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 272. Asia Pacific Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 273. Asia Pacific Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 274. Asia Pacific Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 275. Asia Pacific Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 276. Asia Pacific Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 277. Asia Pacific Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 278. Asia Pacific Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 279. Asia Pacific Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 280. Asia Pacific Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 281. Asia Pacific Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 282. Asia Pacific Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 283. Asia Pacific Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 284. Asia Pacific Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 285. Asia Pacific Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 286. Asia Pacific Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 287. Asia Pacific Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288. Asia Pacific Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289. Asia Pacific Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290. Asia Pacific Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291. Asia Pacific Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292. Asia Pacific Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293. Asia Pacific Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294. Asia Pacific Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295. Asia Pacific Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 296. Asia Pacific Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 297. Asia Pacific Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 298. Asia Pacific Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 299. Asia Pacific Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 300. Asia Pacific Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 301. Asia Pacific Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 302. Asia Pacific Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 303. Asia Pacific Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 304. Asia Pacific Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 305. Asia Pacific Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 306. China Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 307. China Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 308. China Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 309. China Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 310. China Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 311. India Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 312. India Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 313. India Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 314. India Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 315. India Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 316. Japan Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 317. Japan Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 318. Japan Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 319. Japan Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 320. Japan Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 321. RoAPAC Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 322. RoAPAC Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 323. RoAPAC Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 324. RoAPAC Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 325. RoAPAC Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 326. Middle East Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 327. Middle East Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 328. Middle East Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 329. Middle East Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 330. Middle East Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 331. Middle East Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 332. Middle East Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 333. Middle East Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 334. Middle East Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 335. Middle East Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 336. Middle East Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 337. Middle East Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 338. Middle East Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 339. Middle East Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 340. Middle East Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 341. Middle East Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 342. Middle East Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 343. Middle East Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 344. Middle East Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 345. Middle East Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 346. Middle East Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 347. Middle East Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 348. Middle East Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 349. Middle East Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 350. Middle East Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 351. Middle East Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 352. Middle East Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 353. Middle East Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 354. Middle East Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 355. Middle East Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 356. Latin America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 357. Latin America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 358. Latin America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 359. Latin America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 360. Latin America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 361. Latin America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 362. Latin America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 363. Latin America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 364. Latin America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 365. Latin America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 366. Latin America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 367. Latin America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 368. Latin America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 369. Latin America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 370. Latin America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 371. Latin America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 372. Latin America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 373. Latin America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 374. Latin America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 375. Latin America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 376. Latin America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 377. Latin America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 378. Latin America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 379. Latin America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 380. Latin America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 381. Latin America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 382. Latin America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 383. Latin America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 384. Latin America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 385. Latin America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 386. Africa Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 387. Africa Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 388. Africa Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 389. Africa Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 390. Africa Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 391. Africa Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 392. Africa Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 393. Africa Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 394. Africa Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 395. Africa Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 396. Africa Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 397. Africa Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 398. Africa Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 399. Africa Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 400. Africa Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 401. Africa Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 402. Africa Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 403. Africa Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 404. Africa Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 405. Africa Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 406. Africa Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 407. Africa Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 408. Africa Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 409. Africa Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 410. Africa Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 411. Africa Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 412. Africa Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 413. Africa Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 414. Africa Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 415. Africa Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 416. Porter’s Five Force Analysis
Companies Mentioned
1. AbbVie
2. Achaogen
3. Actavis
4. Actelion
5. Affinium Pharmaceutical
6. AiCuris GmbH & Co. KG
7. Alcon
8. Alkem Laboratories
9. Allergan
10. Allied Pharma
11. Apotex
12. APP Pharmaceuticals
13. Aptalis Pharma
14. Aquapharm Biodiscovery
15. Cempra Pharmaceuticals
16. Cipla
17. Claris Lifesciences
18. Cornerstone Biopharma
19. Cornerstone Therapeutics
20. Corona Remedies
21. Eli Lilly
22. Gate Pharma
23. Gilead Sciences
24. GlaxoSmithKline (GSK)
25. Glenmark
26. GlycoVaxyn
27. Hetero
28. Hikma Farmaceutica
29. Hi-Tech Pharma
30. Hospira
31. Macleod Pharmaceuticals
32. Microlabs
33. Nalneva
34. Novartis
35. Novexel
36. Paratek Pharmaceuticals
37. Pfizer
38. Ranbaxy
39. Roche
40. Sagent Pharmaceuticals
41. Sandoz
42. Sanofi
43. Sequella
44. Shanghai MengKe Pharmaceuticals
45. Shionogi
46. SHIONOGI Co., Ltd.
47. Shire
48. Sidmak Labs
49. Solitaire Pharmacia
50. Specialised Therapeutics Australia
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Pharmaceutical Excipients Market
2.1. Pharmaceutical Excipients Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Condition Submarkets Definitions
3. Pharmaceutical Excipients Market Overview
3.1. Global Pharmaceutical Excipients Market Size and Forecast By Region
3.2. Global Pharmaceutical Excipients Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Rapid Surge in the generics demand
3.3.1.2. Increasing geriatric population around the world
3.3.1.3. Increasing strategic initiatives in pharmaceutical excipients market
3.3.1.4. Growing regulatory approvals
3.3.2. Market Restraints
3.3.2.1. Stringent regulation associated with product development
3.3.2.2. High cost of development
3.3.3. Opportunities
3.3.3.1. Increasing therapeutic advancements in pharmaceutical excipients
3.3.3.2. Increasing investment in the pharmaceutical excipients
3.3.4. Challenges
3.3.4.1. Increasing environment concerns around the world
3.3.4.2. Rapid changes in export & import policies
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Pharmaceutical Excipients Market Analysis and Forecast 2021-2031, By Product (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Organic Chemicals
4.1.1.1. Organic Chemicals market size and forecast, 2021-2031 (USD Million)
4.1.2. Inorganic Chemicals
4.1.2.1. Inorganic Chemicals market size and forecast, 2021-2031 (USD Million)
4.1.3. Other Chemicals
4.1.3.1. Other Chemicals market size and forecast, 2021-2031 (USD Million)
5. Global Pharmaceutical Excipients Market Analysis and Forecast, 2021-2031 By Functionality (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Fillers & Diluents
5.1.1.1. Fillers & Diluents market size and forecast, 2021-2031 (USD Million)
5.1.2. Suspending & Viscosity Agents
5.1.2.1. Suspending & Viscosity Agents market size and forecast, 2021-2031 (USD Million)
5.1.3. Coating Agents
5.1.3.1. Coating Agents market size and forecast, 2021-2031 (USD Million)
5.1.4. Binders
5.1.4.1. Binders market size and forecast, 2021-2031 (USD Million)
5.1.5. Flavoring Agents & Sweeteners
5.1.5.1. Flavoring Agents & Sweeteners market size and forecast, 2021-2031 (USD Million)
5.1.6. Disintegrants
5.1.6.1. Disintegrants market size and forecast, 2021-2031 (USD Million)
5.1.7. Colorants
5.1.7.1. Colorants market size and forecast, 2021-2031 (USD Million)
5.1.8. Lubricants & Glidants
5.1.8.1. Lubricants & Glidants market size and forecast, 2021-2031 (USD Million)
5.1.9. Preservatives
5.1.9.1. Preservatives market size and forecast, 2021-2031 (USD Million)
5.1.10. Emulsifying Agents
5.1.10.1. Emulsifying Agents market size and forecast, 2021-2031 (USD Million)
5.1.11. Others
5.1.11.1. Others market size and forecast, 2021-2031 (USD Million)
6. Global Pharmaceutical Excipients Market Analysis and Forecast, 2021-2031 By Patient Demographics (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Geriatric
6.1.1.1. Geriatric market size and forecast, 2021-2031 (USD Million)
6.1.2. Adult
6.1.2.1. Adult market size and forecast, 2021-2031 (USD Million)
6.1.3. Pediatric
6.1.3.1. Pediatric market size and forecast, 2021-2031 (USD Million)
7. Global Pharmaceutical Excipients Market Analysis and Forecast, 2021-2031 Type of Formulation (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Oral Formulations
7.1.1.1. Oral Formulations market size and forecast, 2021-2031 (USD Million)
7.1.2. Topical Formulations
7.1.2.1. Topical Formulations market size and forecast, 2021-2031 (USD Million)
7.1.3. Parenteral Formulations
7.1.3.1. Parenteral Formulations market size and forecast, 2021-2031 (USD Million)
7.1.4. Other Formulations
7.1.4.1. Other Formulations market size and forecast, 2021-2031 (USD Million)
8. Global Pharmaceutical Excipients Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Hospitals
8.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
8.1.2. Homecare
8.1.2.1. Homecare market size and forecast, 2021-2031 (USD Million)
8.1.3. Specialty Clinics
8.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
8.1.4. Others
8.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
9. Global Pharmaceutical Excipients Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.1.1. Hospitals Pharmacy
9.1.1.1. Hospitals Pharmacy market size and forecast, 2021-2031 (USD Million)
9.1.2. Retail Pharmacy
9.1.2.1. Retail Pharmacy market size and forecast, 2021-2031 (USD Million)
9.1.3. Online Pharmacies
9.1.3.1. Online Pharmacies market size and forecast, 2021-2031 (USD Million)
10. North America Pharmaceutical Excipients Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. North America Pharmaceutical Excipients Market Size and Forecast By Product
10.2.1.1. XX Driving/Opportunity Factor
10.2.1.2. XX Driving/Opportunity Factor
10.3. North America Pharmaceutical Excipients Market Size and Forecast By Functionality
10.3.1.1. XX Driving/Opportunity Factor
10.3.1.2. XX Driving/Opportunity Factor
10.4. North America Pharmaceutical Excipients Market Size and Forecast Type of Formulation
10.4.1.1. XX Driving/Opportunity Factor
10.4.1.2. XX Driving/Opportunity Factor
10.5. North America Pharmaceutical Excipients Market Size and Forecast By Patient Demographics
10.5.1.1. XX Driving/Opportunity Factor
10.5.1.2. XX Driving/Opportunity Factor
10.6. North America Pharmaceutical Excipients Market Size and Forecast By End-User
10.6.1.1. XX Driving/Opportunity Factor
10.6.1.2. XX Driving/Opportunity Factor
10.7. North America Pharmaceutical Excipients Market Size and Forecast By Distribution Channel
10.7.1.1. XX Driving/Opportunity Factor
10.7.1.2. XX Driving/Opportunity Factor
10.8. U.S. Pharmaceutical Excipients Market
10.8.1.1. XX Driving/Opportunity Factor
10.8.1.2. XX Driving/Opportunity Factor
10.9. Canada Pharmaceutical Excipients Market
10.9.1.1. XX Driving/Opportunity Factor
10.9.1.2. XX Driving/Opportunity Factor
11. Europe Pharmaceutical Excipients Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. Europe Pharmaceutical Excipients Market Size and Forecast By Product
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. Europe Pharmaceutical Excipients Market Size and Forecast By Functionality
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. Europe Pharmaceutical Excipients Market Size and Forecast By Patient Demographics
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. Europe Pharmaceutical Excipients Market Size and Forecast Type of Formulation
11.5.1.1. XX Driving/Opportunity Factor
11.5.1.2. XX Driving/Opportunity Factor
11.6. Europe Pharmaceutical Excipients Market Size and Forecast By End-User
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. Europe Pharmaceutical Excipients Market Size and Forecast By Distribution Channel
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. UK Pharmaceutical Excipients Market
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
11.9. Germany Pharmaceutical Excipients Market
11.9.1.1. XX Driving/Opportunity Factor
11.9.1.2. XX Driving/Opportunity Factor
11.10. France Pharmaceutical Excipients Market
11.10.1.1. XX Driving/Opportunity Factor
11.10.1.2. XX Driving/Opportunity Factor
11.11. Rest of Europe Pharmaceutical Excipients Market
11.11.1.1. XX Driving/Opportunity Factor
11.11.1.2. XX Driving/Opportunity Factor
12. Asia Pacific Pharmaceutical Excipients Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. Asia-Pacific Pharmaceutical Excipients Market Size and Forecast By Product
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. Asia-Pacific Pharmaceutical Excipients Market Size and Forecast By Functionality
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. Asia-Pacific Pharmaceutical Excipients Market Size and Forecast By Patient Demographics
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. Asia-Pacific Pharmaceutical Excipients Market Size and Forecast Type of Formulation
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. Asia-Pacific Pharmaceutical Excipients Market Size and Forecast By End-User
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. Asia-Pacific Pharmaceutical Excipients Market Size and Forecast By Distribution Channel
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. China Pharmaceutical Excipients Market
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. India Pharmaceutical Excipients Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
12.10. Japan Pharmaceutical Excipients Market
12.10.1.1. XX Driving/Opportunity Factor
12.10.1.2. XX Driving/Opportunity Factor
12.11. Rest of Asia Pacific Pharmaceutical Excipients Market
12.11.1.1. XX Driving/Opportunity Factor
12.11.1.2. XX Driving/Opportunity Factor
13. Latin America Pharmaceutical Excipients Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. Latin America Pharmaceutical Excipients Market Size and Forecast By Product
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. Latin America Pharmaceutical Excipients Market Size and Forecast By Functionality
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. Latin America Pharmaceutical Excipients Market Size and Forecast By Patient Demographics
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. Latin America Pharmaceutical Excipients Market Size and Forecast Type of Formulation
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. Latin America Pharmaceutical Excipients Market Size and Forecast By End-User
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. Latin America Pharmaceutical Excipients Market Size and Forecast By Distribution Channel
13.8. Brazil Pharmaceutical Excipients Market
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. Mexico Pharmaceutical Excipients Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
13.10. Rest of Latin America Pharmaceutical Excipients Market
13.10.1.1. XX Driving/Opportunity Factor
13.10.1.2. XX Driving/Opportunity Factor
14. MEA Pharmaceutical Excipients Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
14.1. Market Overview
14.2. MEA Pharmaceutical Excipients Market Size and Forecast By Product
14.2.1.1. XX Driving/Opportunity Factor
14.2.1.2. XX Driving/Opportunity Factor
14.3. MEA Pharmaceutical Excipients Market Size and Forecast By Functionality
14.3.1.1. XX Driving/Opportunity Factor
14.3.1.2. XX Driving/Opportunity Factor
14.4. MEA Pharmaceutical Excipients Market Size and Forecast By Patient Demographics
14.4.1.1. XX Driving/Opportunity Factor
14.4.1.2. XX Driving/Opportunity Factor
14.5. MEA Pharmaceutical Excipients Market Size and Forecast Type of Formulation
14.5.1.1. XX Driving/Opportunity Factor
14.5.1.2. XX Driving/Opportunity Factor
14.6. MEA Pharmaceutical Excipients Market Size and Forecast By End-User
14.6.1.1. XX Driving/Opportunity Factor
14.6.1.2. XX Driving/Opportunity Factor
14.7. MEA Pharmaceutical Excipients Market Size and Forecast By Distribution Channel
14.7.1.1. XX Driving/Opportunity Factor
14.7.1.2. XX Driving/Opportunity Factor
14.8. GCC Pharmaceutical Excipients Market
14.8.1.1. XX Driving/Opportunity Factor
14.8.1.2. XX Driving/Opportunity Factor
14.9. South Africa Pharmaceutical Excipients Market
14.9.1.1. XX Driving/Opportunity Factor
14.9.1.2. XX Driving/Opportunity Factor
14.10. Rest of MEA Pharmaceutical Excipients Market
14.10.1.1. XX Driving/Opportunity Factor
14.10.1.2. XX Driving/Opportunity Factor
15. Companies in the Pharmaceutical Excipients Market
15.1. Dupont De Nemours, Inc.
15.1.1. Company Snapshot
15.1.2. Company Overview
15.1.3. Financial Performance (2015-2019)
15.1.3.1. Net Revenue
15.1.3.2. Gross Profit
15.1.3.3. Geographical Revenue, 2019
15.1.4. Product Offerings
15.1.5. Recent Initiatives (2017-2019)
15.2. Roquette Frères
15.2.1. Company Snapshot
15.2.2. Company Overview
15.2.3. Financial Performance (2015-2019)
15.2.3.1. Net Revenue
15.2.3.2. Gross Profit
15.2.3.3. Geographical Revenue, 2019
15.2.4. Product Offerings
15.2.5. Recent Initiatives (2017-2019)
15.3. Ashland Global Holdings Inc.
15.3.1. Company Snapshot
15.3.2. Company Overview
15.3.3. Financial Performance (2015-2019)
15.3.3.1. Net Revenue
15.3.3.2. Gross Profit
15.3.3.3. Geographical Revenue, 2019
15.3.4. Product Offerings
15.3.5. Recent Initiatives (2017-2019)
15.4. Evonik Industries AG
15.4.1. Company Snapshot
15.4.2. Company Overview
15.4.3. Financial Performance (2015-2019)
15.4.3.1. Net Revenue
15.4.3.2. Gross Profit
15.4.3.3. Geographical Revenue, 2019
15.4.4. Product Offerings
15.4.5. Recent Initiatives (2017-2019)
15.5. BASF SE
15.5.1. Company Snapshot
15.5.2. Company Overview
15.5.3. Financial Performance (2015-2019)
15.5.3.1. Net Revenue
15.5.3.2. Gross Profit
15.5.3.3. Geographical Revenue, 2019
15.5.4. Product Offerings
15.5.5. Recent Initiatives (2017-2019)
15.6. Kerry Group PLC
15.6.1. Company Snapshot
15.6.2. Company Overview
15.6.3. Financial Performance (2015-2019)
15.6.3.1. Net Revenue
15.6.3.2. Gross Profit
15.6.3.3. Geographical Revenue, 2019
15.6.4. Product Offerings
15.6.5. Recent Initiatives (2017-2019)
15.7. Croda International
15.7.1. Company Snapshot
15.7.2. Company Overview
15.7.3. Financial Performance (2015-2019)
15.7.3.1. Net Revenue
15.7.3.2. Gross Profit
15.7.3.3. Geographical Revenue, 2019
15.7.4. Product Offerings
15.7.5. Recent Initiatives (2017-2019)
15.8. Associated British Foods PLC
15.8.1. Company Snapshot
15.8.2. Company Overview
15.8.3. Financial Performance (2015-2019)
15.8.3.1. Net Revenue
15.8.3.2. Gross Profit
15.8.3.3. Geographical Revenue, 2019
15.8.4. Product Offerings
15.8.5. Recent Initiatives (2017-2019)
15.9. Archer Daniels Midland Company
15.9.1. Company Snapshot
15.9.2. Company Overview
15.9.3. Financial Performance (2015-2019)
15.9.3.1. Net Revenue
15.9.3.2. Gross Profit
15.9.3.3. Geographical Revenue, 2019
15.9.4. Product Offerings
15.9.5. Recent Initiatives (2017-2019)
15.10. Lubrizol Corporation
15.10.1. Company Snapshot
15.10.2. Company Overview
15.10.3. Financial Performance (2015-2019)
15.10.3.1. Net Revenue
15.10.3.2. Gross Profit
15.10.3.3. Geographical Revenue, 2019
15.10.4. Product Offerings
15.10.5. Recent Initiatives (2017-2019)
15.11. Other Notable Players
16. Conclusion
17. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Pharmaceutical Excipients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Pharmaceutical Excipients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Pharmaceutical Excipients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Pharmaceutical Excipients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Pharmaceutical Excipients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Pharmaceutical Excipients Market Drivers & Restraints 2021
Table 7. Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Organic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Organic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Organic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Organic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Organic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Inorganic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Inorganic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Inorganic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Inorganic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Inorganic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Other Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Other Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Other Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Other Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Other Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Fillers & Diluents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Fillers & Diluents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Fillers & Diluents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Fillers & Diluents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Fillers & Diluents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Suspending & Viscosity Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Suspending & Viscosity Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Suspending & Viscosity Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Suspending & Viscosity Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Suspending & Viscosity Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Coating Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Coating Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Coating Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Coating Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Coating Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Binders Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Binders Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Binders Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Binders Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Binders Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Disintegrants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Disintegrants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Disintegrants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Disintegrants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Disintegrants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Colorants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Colorants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Colorants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Colorants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Colorants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Lubricants & Glidants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Lubricants & Glidants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Lubricants & Glidants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Lubricants & Glidants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Lubricants & Glidants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Preservatives Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Preservatives Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Preservatives Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Preservatives Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Preservatives Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Emulsifying Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Emulsifying Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Emulsifying Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Emulsifying Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Emulsifying Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Parenteral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Parenteral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Parenteral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Parenteral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Parenteral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Oral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Oral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Oral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Oral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Oral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Topical Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Topical Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Topical Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Topical Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Topical Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Other Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 123. Other Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Other Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Other Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Other Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 128. Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 133. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 138. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 143. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 146. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 148. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 153. Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 158. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 163. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 168. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 172. North America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. North America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. North America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. North America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. North America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. North America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. North America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. North America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. North America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. North America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. North America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. North America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. North America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. North America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. North America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. North America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. North America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. North America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. North America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. North America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. North America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. North America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. North America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. North America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. North America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. North America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. North America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. North America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. North America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. North America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. North America Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. North America Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. North America Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. North America Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. North America Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. US Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. US Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. US Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. US Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. US Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212. Canada Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213. Canada Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. Canada Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. Canada Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. Canada Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. Europe Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 218. Europe Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219. Europe Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. Europe Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. Europe Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222. Europe Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 223. Europe Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224. Europe Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225. Europe Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226. Europe Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227. Europe Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 228. Europe Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 229. Europe Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 230. Europe Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 231. Europe Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 232. Europe Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 233. Europe Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 234. Europe Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 235. Europe Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 236. Europe Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 237. Europe Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 238. Europe Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 239. Europe Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 240. Europe Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 241. Europe Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 242. Europe Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 243. Europe Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 244. Europe Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 245. Europe Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 246. Europe Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 247. Europe Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 248. Europe Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 249. Europe Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 250. Europe Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 251. UK Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 252. UK Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 253. UK Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 254. UK Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 255. UK Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 256. Germany Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 257. Germany Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 258. Germany Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 259. Germany Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 260. Germany Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 261. France Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 262. France Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 263. France Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 264. France Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 265. France Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 266. Rest of Europe Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 267. Rest of Europe Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 268. Rest of Europe Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 269. Rest of Europe Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 270. Rest of Europe Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 271. Asia Pacific Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 272. Asia Pacific Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 273. Asia Pacific Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 274. Asia Pacific Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 275. Asia Pacific Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 276. Asia Pacific Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 277. Asia Pacific Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 278. Asia Pacific Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 279. Asia Pacific Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 280. Asia Pacific Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 281. Asia Pacific Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 282. Asia Pacific Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 283. Asia Pacific Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 284. Asia Pacific Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 285. Asia Pacific Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 286. Asia Pacific Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 287. Asia Pacific Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 288. Asia Pacific Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 289. Asia Pacific Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 290. Asia Pacific Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 291. Asia Pacific Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 292. Asia Pacific Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 293. Asia Pacific Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 294. Asia Pacific Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 295. Asia Pacific Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 296. Asia Pacific Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 297. Asia Pacific Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 298. Asia Pacific Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 299. Asia Pacific Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 300. Asia Pacific Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 301. Asia Pacific Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 302. Asia Pacific Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 303. Asia Pacific Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 304. Asia Pacific Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 305. Asia Pacific Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 306. China Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 307. China Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 308. China Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 309. China Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 310. China Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 311. India Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 312. India Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 313. India Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 314. India Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 315. India Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 316. Japan Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 317. Japan Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 318. Japan Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 319. Japan Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 320. Japan Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 321. RoAPAC Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 322. RoAPAC Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 323. RoAPAC Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 324. RoAPAC Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 325. RoAPAC Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 326. Middle East Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 327. Middle East Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 328. Middle East Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 329. Middle East Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 330. Middle East Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 331. Middle East Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 332. Middle East Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 333. Middle East Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 334. Middle East Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 335. Middle East Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 336. Middle East Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 337. Middle East Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 338. Middle East Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 339. Middle East Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 340. Middle East Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 341. Middle East Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 342. Middle East Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 343. Middle East Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 344. Middle East Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 345. Middle East Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 346. Middle East Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 347. Middle East Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 348. Middle East Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 349. Middle East Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 350. Middle East Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 351. Middle East Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 352. Middle East Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 353. Middle East Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 354. Middle East Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 355. Middle East Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 356. Latin America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 357. Latin America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 358. Latin America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 359. Latin America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 360. Latin America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 361. Latin America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 362. Latin America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 363. Latin America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 364. Latin America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 365. Latin America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 366. Latin America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 367. Latin America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 368. Latin America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 369. Latin America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 370. Latin America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 371. Latin America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 372. Latin America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 373. Latin America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 374. Latin America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 375. Latin America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 376. Latin America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 377. Latin America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 378. Latin America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 379. Latin America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 380. Latin America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 381. Latin America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 382. Latin America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 383. Latin America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 384. Latin America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 385. Latin America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 386. Africa Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 387. Africa Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 388. Africa Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 389. Africa Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 390. Africa Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 391. Africa Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 392. Africa Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 393. Africa Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 394. Africa Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 395. Africa Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 396. Africa Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 397. Africa Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 398. Africa Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 399. Africa Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 400. Africa Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 401. Africa Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 402. Africa Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 403. Africa Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 404. Africa Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 405. Africa Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 406. Africa Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 407. Africa Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 408. Africa Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 409. Africa Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 410. Africa Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 411. Africa Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 412. Africa Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 413. Africa Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 414. Africa Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 415. Africa Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 416. Leading 10 Pharmaceutical Excipients Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 417. Dupont De Nemours, Inc.Profile 2019 (CEO, HQ, Founded, Website)
Table 418. Dupont De Nemours, Inc. Pharmaceutical Excipients Product Offering (Segment, Product Offerings)
Table 419. Roquette Frères Profile 2019 (CEO, HQ, Founded, Website)
Table 420. Roquette Frères Pharmaceutical Excipients Product Offering (Segment, Product Offerings)
Table 421. Ashland Global Holdings Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 422. Ashland Global Holdings Inc..Pharmaceutical Excipients Product Offering (Segment, Product Offerings)
Table 423. Evonik Industries AG Profile 2019 (CEO, HQ, Founded, Website)
Table 424. Evonik Industries AG Pharmaceutical Excipients Product Offering (Segment, Product Offerings)
Table 425. BASF SE Profile 2019 (CEO, HQ, Founded, Website)
Table 426. BASF SE Pharmaceutical Excipients Product Offering (Segment, Product Offerings)
Table 427. Kerry Group PLC Profile 2019 (CEO, HQ, Founded, Website)
Table 428. Kerry Group PLC Pharmaceutical Excipients Product Offering (Segment, Product Offerings)
Table 429. Croda International Profile 2019 (CEO, HQ, Founded, Website)
Table 430. Croda International Pharmaceutical Excipients Product Offering (Segment, Product Offerings)
Table 431. Associated British Foods PLC Profile 2019 (CEO, HQ, Founded, Website)
Table 432. Associated British Foods PLC Pharmaceutical Excipients Product Offering (Segment, Product Offerings)
Table 433. Archer Daniels Midland Company Profile 2019 (CEO, HQ, Founded, Website)
Table 434. Archer Daniels Midland Company Pharmaceutical Excipients Product Offering (Segment, Product Offerings)
Table 435. Lubrizol Corporation Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 436. Lubrizol Corporation Pharmaceutical Excipients Product Offering (Segment, Product Offerings)
Table 437. Other Companies Involved in the Pharmaceutical Excipients Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Pharmaceutical Excipients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Pharmaceutical Excipients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Pharmaceutical Excipients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Pharmaceutical Excipients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Pharmaceutical Excipients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Pharmaceutical Excipients Market Drivers & Restraints 2021
Figure 7. Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. Organic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. Organic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. Organic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. Organic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. Organic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Inorganic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Inorganic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Inorganic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Inorganic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Inorganic Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Other Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Other Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Other Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Other Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Other Chemicals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Fillers & Diluents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33. Fillers & Diluents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Fillers & Diluents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Fillers & Diluents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Fillers & Diluents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Suspending & Viscosity Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Suspending & Viscosity Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Suspending & Viscosity Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Suspending & Viscosity Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Suspending & Viscosity Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Coating Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Coating Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Coating Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Coating Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Coating Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Binders Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Binders Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Binders Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Binders Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Binders Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Disintegrants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Disintegrants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Disintegrants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Disintegrants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Disintegrants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Colorants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Colorants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Colorants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Colorants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Colorants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Lubricants & Glidants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Lubricants & Glidants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Lubricants & Glidants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Lubricants & Glidants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Lubricants & Glidants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Preservatives Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Preservatives Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Preservatives Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Preservatives Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Preservatives Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Emulsifying Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Emulsifying Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Emulsifying Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Emulsifying Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Emulsifying Agents Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Geriatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Adult Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Parenteral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Parenteral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Parenteral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Parenteral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Parenteral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Oral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Oral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Oral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Oral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Oral Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. Topical Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 118. Topical Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. Topical Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. Topical Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. Topical Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. Other Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 123. Other Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. Other Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. Other Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. Other Formulations Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 128. Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 133. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 138. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 143. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 148. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 153. Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 158. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 163. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 168. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. North America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 173. North America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 174. North America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 175. North America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 176. North America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 177. North America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 178. North America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 179. North America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 180. North America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 181. North America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 182. North America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 183. North America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 184. North America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 185. North America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 186. North America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 187. North America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 188. North America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 189. North America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 190. North America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 191. North America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 192. North America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 193. North America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 194. North America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 195. North America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 196. North America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 197. North America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 198. North America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 199. North America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 200. North America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 201. North America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 202. North America Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 203. North America Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 204. North America Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 205. North America Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 206. North America Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 207. US Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 208. US Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 209. US Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 210. US Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 211. US Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 212. Canada Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 213. Canada Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 214. Canada Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 215. Canada Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 216. Canada Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 217. Europe Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 218. Europe Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 219. Europe Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 220. Europe Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 221. Europe Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 222. Europe Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 223. Europe Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 224. Europe Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 225. Europe Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 226. Europe Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 227. Europe Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 228. Europe Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 229. Europe Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 230. Europe Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 231. Europe Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 232. Europe Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 233. Europe Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 234. Europe Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 235. Europe Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 236. Europe Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 237. Europe Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 238. Europe Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 239. Europe Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 240. Europe Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 241. Europe Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 242. Europe Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 243. Europe Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 244. Europe Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 245. Europe Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 246. Europe Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 247. Europe Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 248. Europe Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 249. Europe Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 250. Europe Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 251. UK Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 252. UK Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 253. UK Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 254. UK Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 255. UK Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 256. Germany Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 257. Germany Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 258. Germany Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 259. Germany Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 260. Germany Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 261. France Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 262. France Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 263. France Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 264. France Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 265. France Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 266. Rest of Europe Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 267. Rest of Europe Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 268. Rest of Europe Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 269. Rest of Europe Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 270. Rest of Europe Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 271. Asia Pacific Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 272. Asia Pacific Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 273. Asia Pacific Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 274. Asia Pacific Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 275. Asia Pacific Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 276. Asia Pacific Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 277. Asia Pacific Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 278. Asia Pacific Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 279. Asia Pacific Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 280. Asia Pacific Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 281. Asia Pacific Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 282. Asia Pacific Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 283. Asia Pacific Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 284. Asia Pacific Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 285. Asia Pacific Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 286. Asia Pacific Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 287. Asia Pacific Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288. Asia Pacific Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289. Asia Pacific Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290. Asia Pacific Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291. Asia Pacific Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292. Asia Pacific Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293. Asia Pacific Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294. Asia Pacific Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295. Asia Pacific Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 296. Asia Pacific Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 297. Asia Pacific Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 298. Asia Pacific Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 299. Asia Pacific Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 300. Asia Pacific Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 301. Asia Pacific Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 302. Asia Pacific Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 303. Asia Pacific Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 304. Asia Pacific Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 305. Asia Pacific Pharmaceutical Excipients Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 306. China Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 307. China Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 308. China Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 309. China Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 310. China Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 311. India Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 312. India Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 313. India Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 314. India Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 315. India Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 316. Japan Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 317. Japan Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 318. Japan Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 319. Japan Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 320. Japan Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 321. RoAPAC Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 322. RoAPAC Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 323. RoAPAC Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 324. RoAPAC Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 325. RoAPAC Pharmaceutical Excipients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 326. Middle East Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 327. Middle East Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 328. Middle East Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 329. Middle East Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 330. Middle East Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 331. Middle East Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 332. Middle East Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 333. Middle East Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 334. Middle East Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 335. Middle East Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 336. Middle East Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 337. Middle East Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 338. Middle East Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 339. Middle East Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 340. Middle East Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 341. Middle East Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 342. Middle East Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 343. Middle East Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 344. Middle East Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 345. Middle East Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 346. Middle East Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 347. Middle East Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 348. Middle East Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 349. Middle East Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 350. Middle East Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 351. Middle East Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 352. Middle East Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 353. Middle East Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 354. Middle East Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 355. Middle East Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 356. Latin America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 357. Latin America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 358. Latin America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 359. Latin America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 360. Latin America Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 361. Latin America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 362. Latin America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 363. Latin America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 364. Latin America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 365. Latin America Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 366. Latin America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 367. Latin America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 368. Latin America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 369. Latin America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 370. Latin America Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 371. Latin America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 372. Latin America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 373. Latin America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 374. Latin America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 375. Latin America Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 376. Latin America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 377. Latin America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 378. Latin America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 379. Latin America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 380. Latin America Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 381. Latin America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 382. Latin America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 383. Latin America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 384. Latin America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 385. Latin America Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 386. Africa Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 387. Africa Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 388. Africa Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 389. Africa Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 390. Africa Pharmaceutical Excipients Market Forecast By Product 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 391. Africa Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 392. Africa Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 393. Africa Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 394. Africa Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 395. Africa Pharmaceutical Excipients Market Forecast By Functionality 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 396. Africa Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 397. Africa Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 398. Africa Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 399. Africa Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 400. Africa Pharmaceutical Excipients Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 401. Africa Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 402. Africa Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 403. Africa Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 404. Africa Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 405. Africa Pharmaceutical Excipients Market Forecast Type of Formulation 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 406. Africa Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 407. Africa Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 408. Africa Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 409. Africa Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 410. Africa Pharmaceutical Excipients Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 411. Africa Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 412. Africa Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 413. Africa Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 414. Africa Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 415. Africa Pharmaceutical Excipients Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 416. Porter’s Five Force Analysis
Companies Mentioned
1. AbbVie
2. Achaogen
3. Actavis
4. Actelion
5. Affinium Pharmaceutical
6. AiCuris GmbH & Co. KG
7. Alcon
8. Alkem Laboratories
9. Allergan
10. Allied Pharma
11. Apotex
12. APP Pharmaceuticals
13. Aptalis Pharma
14. Aquapharm Biodiscovery
15. Cempra Pharmaceuticals
16. Cipla
17. Claris Lifesciences
18. Cornerstone Biopharma
19. Cornerstone Therapeutics
20. Corona Remedies
21. Eli Lilly
22. Gate Pharma
23. Gilead Sciences
24. GlaxoSmithKline (GSK)
25. Glenmark
26. GlycoVaxyn
27. Hetero
28. Hikma Farmaceutica
29. Hi-Tech Pharma
30. Hospira
31. Macleod Pharmaceuticals
32. Microlabs
33. Nalneva
34. Novartis
35. Novexel
36. Paratek Pharmaceuticals
37. Pfizer
38. Ranbaxy
39. Roche
40. Sagent Pharmaceuticals
41. Sandoz
42. Sanofi
43. Sequella
44. Shanghai MengKe Pharmaceuticals
45. Shionogi
46. SHIONOGI Co., Ltd.
47. Shire
48. Sidmak Labs
49. Solitaire Pharmacia
50. Specialised Therapeutics Australia
Companies Profiled in the Report
1. Dupont De Nemours, Inc.
2. Roquette Frères
3. Ashland Global Holdings Inc.
4. Evonik Industries AG
5. BASF SE
6. Kerry Group PLC
7. Croda International
8. Associated British Foods PLC
9. Archer Daniels Midland Company
10. Lubrizol Corporation
11. Innophos Holdings Inc.
12. WACKER Chemie AG
13. Air Liquide S.A.
14. Colorcon Inc.
15. DMV-Fonterra Excipients GmbH & Co. Kg
List of Companies Mentioned in the Report:
1. AbbVie
2. Achaogen
3. Actavis
4. Actelion
5. Affinium Pharmaceutical
6. AiCuris GmbH & Co. KG
7. Alcon
8. Alkem Laboratories
9. Allergan
10. Allied Pharma
11. Apotex
12. APP Pharmaceuticals
13. Aptalis Pharma
14. Aquapharm Biodiscovery
15. Cempra Pharmaceuticals
16. Cipla
17. Claris Lifesciences
18. Cornerstone Biopharma
19. Cornerstone Therapeutics
20. Corona Remedies
21. Eli Lilly
22. Gate Pharma
23. Gilead Sciences
24. GlaxoSmithKline (GSK)
25. Glenmark
26. GlycoVaxyn
27. Hetero
28. Hikma Farmaceutica
29. Hi-Tech Pharma
30. Hospira
31. Macleod Pharmaceuticals
32. Microlabs
33. Nalneva
34. Novartis
35. Novexel
36. Paratek Pharmaceuticals
37. Pfizer
38. Ranbaxy
39. Roche
40. Sagent Pharmaceuticals
41. Sandoz
42. Sanofi
43. Sequella
44. Shanghai MengKe Pharmaceuticals
45. Shionogi
46. SHIONOGI Co., Ltd.
47. Shire
48. Sidmak Labs
49. Solitaire Pharmacia
50. Specialised Therapeutics Australia
List of Organizations Mentioned in the Report:
1. Centre for Pharmaceutical Administration Health Sciences Authority
2. Central Drug Standard Control Organization (CDSCO)
3. Organisation for Economic Co-operation and Development (OECD)
4. European Medicines Agency (EMA)
5. Food and Drug Administration (FDA)
6. National Institutes of Health (NIH)
7. United Nations (UN)
8. United Nations Office on Drugs and Crime (UNODC)
9. United Nations Statistics Division (UNSD)
10. Statistical Office of the European Union (EUROSTAT)
11. University of Connecticut
12. World Health Organization (WHO)
13. The National Medical Products Administration (NMPA)
14. Indian Council of Medical Research (ICMR)
15. The Therapeutic Goods Administration
16. The Federal Institute for Drugs and Medical Devices (BfArM)
17. Pharmaceuticals and Medical Devices Agency (PMDA)
18. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
19. Ministry of Health, Labour & Welfare(MHLW)
20. Medicines and Healthcare Products Regulatory Agency (MHRA)
1. Dupont De Nemours, Inc.
2. Roquette Frères
3. Ashland Global Holdings Inc.
4. Evonik Industries AG
5. BASF SE
6. Kerry Group PLC
7. Croda International
8. Associated British Foods PLC
9. Archer Daniels Midland Company
10. Lubrizol Corporation
11. Innophos Holdings Inc.
12. WACKER Chemie AG
13. Air Liquide S.A.
14. Colorcon Inc.
15. DMV-Fonterra Excipients GmbH & Co. Kg
List of Companies Mentioned in the Report:
1. AbbVie
2. Achaogen
3. Actavis
4. Actelion
5. Affinium Pharmaceutical
6. AiCuris GmbH & Co. KG
7. Alcon
8. Alkem Laboratories
9. Allergan
10. Allied Pharma
11. Apotex
12. APP Pharmaceuticals
13. Aptalis Pharma
14. Aquapharm Biodiscovery
15. Cempra Pharmaceuticals
16. Cipla
17. Claris Lifesciences
18. Cornerstone Biopharma
19. Cornerstone Therapeutics
20. Corona Remedies
21. Eli Lilly
22. Gate Pharma
23. Gilead Sciences
24. GlaxoSmithKline (GSK)
25. Glenmark
26. GlycoVaxyn
27. Hetero
28. Hikma Farmaceutica
29. Hi-Tech Pharma
30. Hospira
31. Macleod Pharmaceuticals
32. Microlabs
33. Nalneva
34. Novartis
35. Novexel
36. Paratek Pharmaceuticals
37. Pfizer
38. Ranbaxy
39. Roche
40. Sagent Pharmaceuticals
41. Sandoz
42. Sanofi
43. Sequella
44. Shanghai MengKe Pharmaceuticals
45. Shionogi
46. SHIONOGI Co., Ltd.
47. Shire
48. Sidmak Labs
49. Solitaire Pharmacia
50. Specialised Therapeutics Australia
List of Organizations Mentioned in the Report:
1. Centre for Pharmaceutical Administration Health Sciences Authority
2. Central Drug Standard Control Organization (CDSCO)
3. Organisation for Economic Co-operation and Development (OECD)
4. European Medicines Agency (EMA)
5. Food and Drug Administration (FDA)
6. National Institutes of Health (NIH)
7. United Nations (UN)
8. United Nations Office on Drugs and Crime (UNODC)
9. United Nations Statistics Division (UNSD)
10. Statistical Office of the European Union (EUROSTAT)
11. University of Connecticut
12. World Health Organization (WHO)
13. The National Medical Products Administration (NMPA)
14. Indian Council of Medical Research (ICMR)
15. The Therapeutic Goods Administration
16. The Federal Institute for Drugs and Medical Devices (BfArM)
17. Pharmaceuticals and Medical Devices Agency (PMDA)
18. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
19. Ministry of Health, Labour & Welfare(MHLW)
20. Medicines and Healthcare Products Regulatory Agency (MHRA)
Download sample pages
Complete the form below to download your free sample pages for Pharmaceutical Excipients Market Report 2021-2031Download sample pages
Complete the form below to download your free sample pages for Pharmaceutical Excipients Market Report 2021-2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: jamie.roberts@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Jamie Roberts stating your chosen report title to jamie.roberts@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email jamie.roberts@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034
The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.
18 April 2024
Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034
The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.
17 April 2024
Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034
The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.
12 April 2024
Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034
The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.
11 April 2024
